GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » FCF Yield %

Axonics (Axonics) FCF Yield % : -0.47 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Axonics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Axonics's Trailing 12-Month Free Cash Flow is $-16.3 Mil, and Market Cap is $3,440.2 Mil. Therefore, Axonics's FCF Yield % for today is -0.47%.

The historical rank and industry rank for Axonics's FCF Yield % or its related term are showing as below:

AXNX' s FCF Yield % Range Over the Past 10 Years
Min: -15.36   Med: -3.05   Max: 0.38
Current: -0.47


During the past 8 years, the highest FCF Yield % of Axonics was 0.38%. The lowest was -15.36%. And the median was -3.05%.

AXNX's FCF Yield % is ranked better than
59.17% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -2.63 vs AXNX: -0.47

Axonics's FCF Margin % for the quarter that ended in Mar. 2024 was -13.45%.


Axonics FCF Yield % Historical Data

The historical data trend for Axonics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics FCF Yield % Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial -8.97 -4.35 -1.91 0.03 -0.18

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -3.06 1.57 0.55 -1.40

Competitive Comparison of Axonics's FCF Yield %

For the Medical Devices subindustry, Axonics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Axonics's FCF Yield % falls into.



Axonics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Axonics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-5.566 / 3159.448215
=-0.18%

Axonics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-12.295 * 4 / 3518.725254
=-1.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axonics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Axonics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Axonics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920